PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2

Complete if Known	
Application Number	10/501,628
Filing Date	November 22, 2004
First Named Inventor	Alberto Martin
Art Unit	1633
Examiner Name	Michael D. Burkhart
Attorney Docket Number	96700/905

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1	BEMARK M et al., entitled "Somatic Hypermutation in the Absense of DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) or Recombination-activating Gene (RAG)1 Activity,"	
		J. Exp. Med., Vol. 192, No. 10, November 20, 2000, 1509-1514.	
	2	DELKER R K et al., entitled "A coming-of-age story: activation-induced cytidine deaminase turns 10," Nat Immunol, 2009 Nov;10(11):1147-53.	
	3	DIAZ M et al., entitled "Evolution and the molecular basis of somatic hypermutation of antigen receptor genes," Phil. Trans. R. Soc. Lond. B 2001, 356, 67-72.	
	4	GINGRICH J A et al., entitled "The broken mouse: the role of development, plasticity and environment in the interpretation of phenotypic changes in knockout mice,"	
		Current Opinion in Neurobiology 2000, 10:146-152.	
	5	JACOBS H et al., entitled "Towards an understanding of somatic hypermutation," Current Opinion in Immunology 2001, 13:208-218.	
	6	LIU J et al., entitled "Conditional Knockout of Mouse Insulin-Like Growth Factor-1 Gene Using the Cre/loxP System (44500)," P.S.E.B.M. 2000, Vol. 223:344-351.	
	7	MURAMATSU M et al. "Specific Expression of Activation-induced Cytidine Deaminase (AID), a Novel Member of the RNA-editing Deaminase Family in Germinal Center B Cells"	
		The Journal of Biological Chemistry, Vol. 274, No. 26, Issue of June 25, 18470-18476, 1999.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/501,628
Filing Date	November 22, 2004
First Named Inventor	Alberto Martin
Art Unit	1633
Examiner Name	Michael D. Burkhart
Attorney Docket Number	96700/905

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	8	ROGOZIN I B et al., entitled "Somatic mutation hotspots correlate with DNA polymerase η error spectrum," Nature Immunology, Vol. 2, No. 6, June 2001, 530-536.	
	9	ZAN H et al., entitled "The Translesion DNA Polymerase ζ Plays a Major Role in Ig and bcl-6 Somatic Hypermutation," Immunity, Vol. 14, 643-653, May 2001.	
	10	ZENG X et al., entitled "DNA polymerase η is an A-T mutator in somatic hypermutation of immunoglobulin variable genes," Nature Immunology, June 2001, Vol. 2, No. 6, 537-541.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.